ArticleThe British journal of surgery2026
Multimodal prehabilitation and perioperative immune function in patients undergoing abdominal cancer surgery.
Article in The British journal of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrehabilitation is an emerging preoperative strategy designed to optimize patients' functional capacity before surgery to improve postoperative outcomes. Previous studies have demonstrated its clinical benefit, including enhanced recovery and reduced postoperative complications. However, the mechanisms underlying these benefits remain poorly understood. The aim of this exploratory study was to investigate the potential effects of prehabilitation on preoperative and postoperative immune function.
methodsThis prospective study utilized data and material from a subgroup of patients participating in the F4S PREHAB trial (NL73777.091.20), which is a stepped-wedge trial investigating the effects of multimodal prehabilitation before major surgery. In this substudy, patients who underwent elective bladder, oesophageal, or rectal cancer surgery between June 2022 and November 2023 were included. Immune function was assessed at baseline, after the prehabilitation or usual care interval, and on postoperative day 1 (POD1) by examining ex vivo cytokine production capacity, plasma cytokine concentrations, and monocytic human leucocyte antigen DR (mHLA-DR) expression.
resultsThis substudy included 130 patients: 102 in the prehabilitation group and 28 in the control group. After prehabilitation, the ex vivo production of pro-inflammatory cytokines was reduced, whereas the ex vivo production of the anti-inflammatory cytokine interleukin 10 (IL-10) was increased. Plasma concentrations of interleukin 6 (IL-6) and IL-10 were lower after prehabilitation. On POD1, no significant differences in postoperative immune function were observed between the prehabilitation and control groups.
conclusionThis study suggests that multimodal prehabilitation influences basal immune function, leading to a less inflammatory state. However, as no significant differences in immune function were observed between the prehabilitation and control groups on POD1, the impact of prehabilitation on postoperative immune function may be limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.